Lymphoproliferative Disorders Program, Novant Health, Charlotte, North Carolina, USA.
Curr Opin Hematol. 2019 Nov;26(6):421-426. doi: 10.1097/MOH.0000000000000544.
CART cell therapy has changed the treatment landscape for relapsed/refractory aggressive lymphomas. In this article, we review the CART constructs most studied in lymphoma and their applicability.
Results of ZUMA-1, JULIET and TRANSCEND trials will be reviewed. Real-world data will also be reviewed.
CART cell therapy is evolving and becoming safer. Increased uptake of this modality outside of clinical trials is expected.
嵌合抗原受体 T 细胞（CART）疗法改变了复发/难治性侵袭性淋巴瘤的治疗格局。本文综述了在淋巴瘤中研究最多的 CART 构建体及其适用性。
将回顾 ZUMA-1、JULIET 和 TRANSCEND 试验的结果。还将回顾真实世界的数据。
CART 细胞疗法正在不断发展并变得更加安全。预计这种治疗模式在临床试验之外的应用将会增加。
